In a study of 724 patients who received 100 to 200 milligrams a day of thalidomide or the placebo for up to two years, the median overall survival for patients in the thalidomide group was 10.1 months, compared to 10.5 months for those in the placebo group. Those on the drug increased their risk of blood clots. According to researchers, there is a need to take a new look at the basic biology of small cell lung cancer. Thalidomide, used as a treatment for morning sickness, was banned after it led to birth defects.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지